Skip to main content

An update on an incident involving one of our systems

Hide
Quest Diagnostics

Evaluating Testing Patterns and Prevalence Estimates of Hepatitis B Virus and Latent Tuberculosis Co-Infection from 2016 to 2020: A National Clinical Laboratory Database Analysis

AASLD 2021: American Association for the Study of Liver Disease
Anaheim, CA, November 12-15, 2021

Evaluating Testing Patterns and Prevalence Estimates of Hepatitis B Virus and Latent Tuberculosis Co-Infection from 2016 to 2020: A National Clinical Laboratory Database Analysis

Authors: Wong RJ, Kaufman HW, Niles JK, Meyer WA, III, Chitnis AS

Specialties: Infectious disease

Download key summary

Related content

Publication
Prevalence of Hepatitis B Virus and Latent Tuberculosis CoInfection in the United States
Publication
Low performance of hepatitis delta virus testing among two national cohorts of chronic hepatitis B patients in the United States
Test FAQ
HBV screen panel with reflexes
On-Demand Webinar
HBV Webinar: From Screening to Functional Cure

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2026 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only. May include AI-generated and/or AI-modified imagery.